ADSTILADRIN (nadofaragene firadenovec-vncg) is a non-replicating adenoviral vector-based gene therapy for intravesical instillation. It is a recombinant adenovirus serotype 5 vector containing a transgene encoding the human interferon alfa-2b (IFNα2b). ADSTILADRIN has a nominal concentration of 3 x 10 11 vp/mL.Nadofaragene firadenovec-vncg has been studied in a clinical trial program that includes 157 patients with high-grade, BCG-unresponsive NMIBC who had been treated with adequate BCG previously and ...February 16. The FDA recently approved the first gene therapy for bladder cancer, Ferring Pharmaceuticals’ Adstiladrin (nadofaragene firadenovec-vncg). Almost three-quarters of oncologists surveyed by Zitter Insights expressed at least moderate interest in the agent, and payers said they likely will manage the drug to label.Nadofaragene firadenovec (nadofaragene firadenovec-vncg; Adstiladrin®) is a non-replicating adenoviral vector-based gene therapy developed by Ferring Pharmaceuticals for the treatment of high ...Adstiladrin® (nadofaragene firadenovec-vncg) is a gene therapy developed as a treatment for adult patients with BCG-unresponsive NMIBC. It is a non-replicating adenovirus vector-based gene therapy containing the gene encoding interferon alfa-2b protein, administered by catheter into the bladder once every three months.We would like to show you a description here but the site won’t allow us.Adstiladrin® (nadofaragene firadenovec-vncg) (Intravesical) Document Number: MH-0691 Last Review Date: 05/04/2023 Date of Origin: 02/02/2023 Dates Reviewed: 02/2023, 05/2023 I. Length of Authorization Coverage will be provided initially for 3 months and may be renewed every 6 months thereafter. II. Dosing Limits Aug 24, 2023 · Nadofaragene firadenovec-vncg has been studied in a clinical trial program that includes 157 patients with high-grade, BCG-unresponsive NMIBC who had been treated with adequate BCG previously and ... Today, the U.S. Food and Drug Administration approved Adstiladrin (nadofaragene firadenovec-vncg), a non-replicating (cannot multiply in human cells) adenoviral vector based gene therapy... Nadofaragene firadenovec-vncg is available as Adstiladrin (Ferring Pharmaceuticals) and is a non-replicating adenoviral vector-based gene therapy for intravesical instillation. Adstiladrin is designed to deliver a copy of a gene encoding a human interferon-alfa 2b (IFNα2b) to the bladder urothelium. ADSTILADRIN (nadofaragene firadenovec-vncg) is a non-replicating adenoviral vector-based gene therapy for intravesical instillation. It is a recombinant adenovirus serotype 5 vector containing a transgene encoding the human interferon alfa-2b (IFNα2b). ADSTILADRIN has a nominal concentration of 3 x 10 11 vp/mL.DB17381. Background. Nadofaragene firadenovec (nadofaragene firadenovec-vncg) is a recombinant non-replicating adenovirus serotype 5 vector containing a transgene encoding human interferon alfa-2b (IFNα2b). 5 It was approved by the FDA on December 2022 for the treatment of high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle ...On December 16, 2022, the Food and Drug Administration approved nadofaragene firadenovec-vncg (Adstiladrin, Ferring Pharmaceuticals) for adult patients with high-risk Bacillus Calmette-Guérin...Adstiladrin® (nadofaragene firadenovec-vncg) (Intravesical) Document Number: MH-0691 Last Review Date: 05/04/2023 Date of Origin: 02/02/2023 Dates Reviewed: 02/2023, 05/2023 I. Length of Authorization Coverage will be provided initially for 3 months and may be renewed every 6 months thereafter. II. Dosing Limits Nadofaragene firadenovec is a non-replicating adenovirus vector-based therapy containing the interferon alfa-2b gene. As described by developer Ferring Pharmaceuticals, the vector enters the cells ...Aug 24, 2023 · Adstiladrin ® (nadofaragene firadenovec-vncg) is a gene therapy developed as a treatment for adult patients with BCG-unresponsive NMIBC. It is a non-replicating adenovirus vector-based gene ... Dec 16, 2022 · Patients received nadofaragene firadenovec-vncg 75 mL intravesical instillation once every 3 months for up to 12 months or until intolerable toxicity or recurrent high-grade disease. Those without ... Background: BCG is the most effective therapy for high-risk non-muscle-invasive bladder cancer. Nadofaragene firadenovec (also known as rAd-IFNa/Syn3) is a replication-deficient recombinant adenovirus that delivers human interferon alfa-2b cDNA into the bladder epithelium, and a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer. Aug 24, 2023 · About Adstiladrin Adstiladrin ® (nadofaragene firadenovec-vncg) is a gene therapy developed as a treatment for adult patients with BCG-unresponsive NMIBC. It is a non-replicating adenovirus vector-based gene therapy containing the gene encoding interferon alfa-2b protein, administered by catheter into the bladder once every three months. Adstiladrin® (nadofaragene firadenovec-vncg) (Intravesical) Document Number: IC-0691 Last Review Date: 02/02/2023 Date of Origin: 02/02/2023 Dates Reviewed: 02/2023 I. Length of Authorization Coverage will be provided initially for 3 months and may be renewed every 6 months. II. Dosing Limits A. Quantity Limit (max daily dose) [NDC Unit]:Find medical information for Adstiladrin (nadofaragene firadenovec-vncg) on epocrates online, including its dosing, contraindications, drug interactions, and pill pictures. Nadofaragene firadenovec-vncg is approved to treat: Non-muscle–invasive bladder cancer with carcinoma in situ . It is used in adults whose cancer does not respond to treatment with bacillus Calmette-Guérin (BCG) and has a high risk of coming back. Adstiladrin® (nadofaragene firadenovec-vncg) (Intravesical) Document Number: IC-0691 Last Review Date: 05/04/2023 Date of Origin: 02/02/2023 Dates Reviewed: 02/2023, 05/2023 I. Length of Authorization Coverage will be provided initially for 3 months and may be renewed every 6 months thereafter. II. Dosing LimitsDec 19, 2022 · The safety and effectiveness of nadofaragene firadenovec-vncg was evaluated in a multicenter clinical study that included 157 patients with high-risk BCG-unresponsive non–muscle-invasive bladder cancer, 98 of whom had BCG-unresponsive carcinoma in situ with or without papillary tumors and could be evaluated for response. Adstiladrin ® (nadofaragene firadenovec-vncg) is a gene therapy developed as a treatment for adult patients with BCG-unresponsive NMIBC. It is a non-replicating adenovirus vector-based gene therapy containing the gene encoding interferon alfa-2b protein, administered by catheter into the bladder once every three months.Nadofaragene firadenovec-vncg has been studied in a clinical trial program that includes 157 patients with high-grade, BCG-unresponsive NMIBC who had been treated with adequate BCG previously and ...Jan 13, 2023 · Proper Name: nadofaragene firadenovec-vncg Tradename: ADSTILADRIN Manufacturer: Ferring Pharmaceuticals A/S Indication: For the treatment of adult patients with high-risk Bacillus Calmette-Guérin... Adstiladrin (nadofaragene firadenovec-vncg), #193 Medical Policy #159 Gene Therapies for Bladder Cancer Please use this form to assist in identifying members who meet Blue Cross Blue Shield of Massachusetts’ (BCBSMA’s) medical necessity criteria for Adstiladrin therapy. For members who do not meet the criteria, submit a letterSlowly instill 75 mL of nadofaragene firadenovec into bladder through catheter, ensuring that complete volume is administered. After instillation, retain drug in bladder for 1 hr. During 1-hour dwell time, reposition patient approximately every 15 minutes from left to right, back and abdomen to maximize bladder surface exposure Jul 27, 2023 · ADSTILADRIN (nadofaragene firadenovec-vncg) is a non-replicating adenoviral vector-based gene therapy for intravesical instillation. It is a recombinant adenovirus serotype 5 vector containing a transgene encoding the human interferon alfa-2b (IFNα2b). ADSTILADRIN has a nominal concentration of 3 x 10 11 vp/mL. Adstiladrin ® (nadofaragene firadenovec-vncg) is a gene therapy developed as a treatment for adult patients with BCG-unresponsive NMIBC. It is a non-replicating adenovirus vector-based gene ...Mar 1, 2023 · Nadofaragene firadenovec (nadofaragene firadenovec-vncg; Adstiladrin ®) is a non-replicating adenoviral vector-based gene therapy developed by Ferring Pharmaceuticals for the treatment of high-risk BCG-unresponsive NMIBC [ 1 ]. Nadofaragene firadenovec received its first approval on 16 Dec 2022 in the USA for the treatment of high-risk BCG ... Nadofaragene firadenovec-vncg is available as Adstiladrin (Ferring Pharmaceuticals) and is a non-replicating adenoviral vector-based gene therapy for intravesical instillation. Adstiladrin is designed to deliver a copy of a gene encoding a human interferon-alfa 2b (IFNα2b) to the bladder urothelium.Ferring’s novel adenovirus vector-based gene therapy Adstiladrin ® (nadofaragene firadenovec-vncg) is the first gene therapy approved for bladder cancer; Efficacy and safety of Adstiladrin supported by Phase 3 results demonstrating that more than half of patients (51% of CIS ± Ta/T1 cohort) achieved a complete response (CR) at three months and of these, 46% continued to remain free of high ...nadofaragene firadenovec-vncg RAD-IFN REPLICATION-DEFICIENT ADENOVIRUS TYPE 5 (AD5) VECTOR ENCODING THE HUMAN INTERFERON ALPHA 2 (IFNA2, INTERFERON ALPHA-2B) GENE UNDER THE CONTROL OF THE CYTOMEGALOVIRUS (CMV) IMMEDIATE-EARLY ENHANCER/PROMOTERDec 16, 2022 · The dating period for nadofaragene firadenovec-vncg shall be 18 months from the date of manufacture when stored below -60°C. The drug product can be stored at the clinical Dec 16, 2022 · Remarks. December 16, 2022: FDA approved nadofaragene firadenovec-vncg (Adstiladrin) for adult patients with high-risk Bacillus Calmette-Guerin ( BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ ( CIS) with or without papillary tumor s. Background: BCG is the most effective therapy for high-risk non-muscle-invasive bladder cancer. Nadofaragene firadenovec (also known as rAd-IFNa/Syn3) is a replication-deficient recombinant adenovirus that delivers human interferon alfa-2b cDNA into the bladder epithelium, and a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer. Dec 21, 2022 · Adstiladrin (nadofaragene firadenovec-vncg) is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. Nadofaragene firadenovec (Adstiladrin®) is an intravesical human IFN-α2b gene-mediated therapy that delivers the IFN-α2b gene to increase IFN-α2b expression [94]. In a phase 3 study, a CR of 53.4% at 3 months was reported in patients with CIS, with 24.3% remaining free of high-grade recurrence at 1 year [94]. Find medical information for Adstiladrin (nadofaragene firadenovec-vncg) on epocrates online, including its dosing, contraindications, drug interactions, and pill pictures.Nadofaragene firadenovec-vncg is a non-replicating adenoviral vector-based gene therapy. “Patients with BCG-unresponsive NMIBC have historically had limited treatment options other than bladder removal surgery,” said Steven A. Boorjian, MD, Carl Rosen professor and chair of the Department of Urology at Mayo Clinic, and lead investigator on ...On December 16, 2022, the Food and Drug Administration approved nadofaragene firadenovec-vncg (Adstiladrin, Ferring Pharmaceuticals) for adult patients with high-risk Bacillus Calmette-Guérin...Nadofaragene firadenovec (nadofaragene firadenovec-vncg; Adstiladrin ®) is a non-replicating adenoviral vector-based gene therapy developed by Ferring Pharmaceuticals for the treatment of high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).J9029 Injection, nadofaragene firadenovec-vncg, per therapeutic dose . Reviews, Revisions, and Approvals Date P&T Approval . Date . Policy created 01.21.20 02.20 Adstiladrin ® (nadofaragene firadenovec-vncg) is a gene therapy developed as a treatment for adult patients with BCG-unresponsive NMIBC. It is a non-replicating adenovirus vector-based gene therapy containing the gene encoding interferon alfa-2b protein, administered by catheter into the bladder once every three months.Adstiladrin® (nadofaragene firadenovec-vncg) (Intravesical) Document Number: IC-0691 Last Review Date: 02/02/2023 Date of Origin: 02/02/2023 Dates Reviewed: 02/2023 I. Length of Authorization Coverage will be provided initially for 3 months and may be renewed every 6 months. II. Dosing Limits A. Quantity Limit (max daily dose) [NDC Unit]:Aug 24, 2023 · Nadofaragene firadenovec-vncg has been studied in a clinical trial program that includes 157 patients with high-grade, BCG-unresponsive NMIBC who had been treated with adequate BCG previously and ... Adstiladrin (nadofaragene firadenovec-vncg), #193 Medical Policy #159 Gene Therapies for Bladder Cancer Please use this form to assist in identifying members who meet Blue Cross Blue Shield of Massachusetts’ (BCBSMA’s) medical necessity criteria for Adstiladrin therapy. For members who do not meet the criteria, submit a letterDec 21, 2022 · Adstiladrin (nadofaragene firadenovec-vncg) is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. We would like to show you a description here but the site won’t allow us. Dec 29, 2022 · Nadofaragene Firadenovec-vncg is a non-replicating adenoviral vector-based gene therapy. The treatment delivers the human interferon alfa-2b gene, which is non-replicating, to the cells in your bladder wall. The interferon alfa-2b gene has anti-tumor effects. The gene therapy increases the level and length of time your bladder wall is exposed ... Nadofaragene firadenovec is indicated for the treatment of adults with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. [1] [3] HistoryIntravesical nadofaragene firadenovec is associated with an acceptable safety profile and promising efficacy outcomes to offer a realistic alternative to chemotherapy and systemic treatment options. These results were consistent with findings from the phase 2 study, which suggest that nadofaragene firadenovec is an efficacious and well ...Jan 20, 2023 · On December 16, 2022, the FDA approved nadofaragene firadenovec-vncg (brand name Adstiladrin) for adult patients with high-risk Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder... Nadofaragene firadenovec-vncg is available as Adstiladrin (Ferring Pharmaceuticals) and is a non-replicating adenoviral vector-based gene therapy for intravesical instillation. Adstiladrin is designed to deliver a copy of a gene encoding a human interferon-alfa 2b (IFNα2b) to the bladder urothelium.Slowly instill 75 mL of nadofaragene firadenovec into bladder through catheter, ensuring that complete volume is administered. After instillation, retain drug in bladder for 1 hr. During 1-hour dwell time, reposition patient approximately every 15 minutes from left to right, back and abdomen to maximize bladder surface exposure Nadofaragene firadenovec (nadofaragene firadenovec-vncg; Adstiladrin ®) is a non-replicating adenoviral vector-based gene therapy developed by Ferring Pharmaceuticals for the treatment of high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).ADSTILADRIN ® (nadofaragene firadenovec-vncg) is the first and only FDA-approved intravesical gene-therapy for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. It is a non-replicating adenovirus ...Nadofaragene firadenovec - FKD Therapies. Alternative Names: AAV-IFN-apha-2b-gene-therapy-FKD-Therapies; Adenovirus-Delivered Interferon Alpha-2b; Adstiladrin; FE-999326; Instiladrin; Nadofaragene firadenovec-vncg;…. See more. Latest Information Update: 02 Feb 2023. Price : $50 *.SILVER SPRING, Md., Dec. 16, 2022 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Adstiladrin (nadofaragene firadenovec-vncg), a non-replicating (cannot multiply in human ...Jun 12, 2023 · ADSTILADRIN ® (nadofaragene firadenovec-vncg) is the first and only FDA-approved intravesical gene-therapy for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG ... J9029 Injection, nadofaragene firadenovec-vncg, per therapeutic dose . Reviews, Revisions, and Approvals Date P&T Approval . Date . Policy created 01.21.20 02.20The recommended nadofaragene firadenovec-vncg dose is 75 mL at a concentration of 3 x 10 11 vp/mL instilled once every three months into the bladder via a urinary catheter. Premedication with an anticholinergic is recommended prior to each instillation.Nadofaragene firadenovec-vncg has been studied in a clinical trial program that includes 157 patients with high-grade, BCG-unresponsive NMIBC who had been treated with adequate BCG previously and ...But in 2022 alone, there were three additional gene therapies approved, including Skysona (elivaldogene autotemcel) [from bluebird bio, Inc.] for cerebral adrenoleukodystrophy, Zynteglo (betibeglogene autotemcel) [from bluebird] for beta-thalassemia and [CSL Behring LLC’s] Hemgenix (etranacogene dezaparvovec-drlb) for hemophilia B. [Ferring ...The FDA has approved nadofaragene firadenovec-vncg (Adstiladrin) for the treatment of patients high-risk Bacillus Calmette Guérin (BCG)–unresponsive non-muscle invasive bladder cancer with carcinoma in-situ plus or minus papillary tumors, according to a press release from the agency. The non-replicating adenoviral vector–based gene therapy ...Adstiladrin (nadofaragene firadenovec-vncg) is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.Nadofaragene Firadenovec-vncg is used to treat patients with high-risk Bacillus Calmette-Guerin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with a tumor type called carcinoma in situ (CIS) with or without papillary tumors. This medicine is to be used only by or under the direct supervision of a doctor.J9029 Injection, nadofaragene firadenovec-vncg, per therapeutic dose . Reviews, Revisions, and Approvals Date P&T Approval . Date . Policy created 01.21.20 02.20 February 16. The FDA recently approved the first gene therapy for bladder cancer, Ferring Pharmaceuticals’ Adstiladrin (nadofaragene firadenovec-vncg). Almost three-quarters of oncologists surveyed by Zitter Insights expressed at least moderate interest in the agent, and payers said they likely will manage the drug to label.Nadofaragene firadenovec is indicated for the treatment of adults with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. [1] [3] HistoryMay 17, 2022 · Anirban P. Mitra, MD, PhD. Nadofaragene firadenovec (Instiladrin) combined with immune checkpoint inhibitors such as pembrolizumab (Keytruda) may play a synergistic role in the treatment of ... Dec 16, 2022 · Nadofaragene firadenovec-vncg was approved for patients with high-risk BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors. The recommended dose is 75 mL at a concentration of 3 × 10 11 vp/mL, instilled once every 3 months into the bladder via a urinary catheter. Nadofaragene firadenovec-vncg (ADSTILADRIN) is a recommended treatment option in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) 1 * A unique way to treat Attacks tumor cells directly while simultaneously activating the innate and adaptive arms of a patient’s immune system to continually fight back 2 Intravesical instillationNadofaragene firadenovec-vncg (ADSTILADRIN) is a recommended treatment option in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) 1 * A unique way to treat Attacks tumor cells directly while simultaneously activating the innate and adaptive arms of a patient’s immune system to continually fight back 2 Intravesical instillationNadofaragene firadenovec-vncg has been studied in a clinical trial program that includes 157 patients with high-grade, BCG-unresponsive NMIBC who had been treated with adequate BCG previously and ...Aug 24, 2023 · Nadofaragene firadenovec-vncg has been studied in a clinical trial program that includes 157 patients with high-grade, BCG-unresponsive NMIBC who had been treated with adequate BCG previously and ... Nadofaragene firadenovec-vncg has been studied in a clinical trial program that includes 157 patients with high-grade, BCG-unresponsive NMIBC who had been treated with adequate BCG previously and ...ADSTILADRIN (nadofaragene firadenovec-vncg) is a non-replicating adenoviral vector-based gene therapy for intravesical instillation. It is a recombinant adenovirus serotype 5 vector containing a transgene encoding the human interferon alfa-2b (IFNα2b). ADSTILADRIN has a nominal concentration of 3 x 10 11 vp/mL.ADSTILADRIN (nadofaragene firadenovec-vncg) is a non-replicating adenoviral vector-based gene therapy for intravesical instillation. It is a recombinant adenovirus serotype 5 vector containing a transgene encoding the human interferon alfa-2b (IFNα2b). ADSTILADRIN has a nominal concentration of 3 x 10 11 vp/mL.
Dec 16, 2022 · The Food and Drug Administration (FDA) approved Adstiladrin (nadofaragene firadenovec-vncg) for the treatment of adults with high-risk, non-muscle invasive bladder cancer, representing the first gene therapy approved for this patient population. In particular, Adstiladrin had been approved for the treatment of high-risk Bacillus Calmette ... . Navy blue shirt women
ADSTILADRIN (nadofaragene firadenovec-vncg) is a non-replicating adenoviral vector-based gene therapy for intravesical instillation. It is a recombinant adenovirus serotype 5 vector containing a transgene encoding the human interferon alfa-2b (IFNα2b). ADSTILADRIN has a nominal concentration of 3 x 10 11 vp/mL. Aug 24, 2023 · Adstiladrin ® (nadofaragene firadenovec-vncg) is a gene therapy developed as a treatment for adult patients with BCG-unresponsive NMIBC. It is a non-replicating adenovirus vector-based gene therapy containing the gene encoding interferon alfa-2b protein, administered by catheter into the bladder once every three months. ® (nadofaragene firadenovec-vncg) HCPCS: J9029 Policy: Requests must be supported by submission of chart notes and patient specific documentation. A. Coverage of the requested drug is provided when all the following are met: a. FDA approved indication b. FDA approved age c. Prescribed by or in consultation with an oncologist d. J9029 Injection, nadofaragene firadenovec-vncg, per therapeutic dose . Reviews, Revisions, and Approvals Date P&T Approval . Date . Policy created 01.21.20 02.20 Adstiladrin ® (nadofaragene firadenovec-vncg) is a gene therapy developed as a treatment for adult patients with BCG-unresponsive NMIBC. It is a non-replicating adenovirus vector-based gene therapy containing the gene encoding interferon alfa-2b protein, administered by catheter into the bladder once every three months.Find medical information for Adstiladrin (nadofaragene firadenovec-vncg) on epocrates online, including its dosing, contraindications, drug interactions, and pill pictures. Anirban P. Mitra, MD, PhD. Nadofaragene firadenovec (Instiladrin) combined with immune checkpoint inhibitors such as pembrolizumab (Keytruda) may play a synergistic role in the treatment of ...The cost-effectiveness of nadofaragene firadenovec will depend upon its price. Pembrolizumab, although not cost-effective in our base-case analysis, is an important alternative in this population with an unmet medical need. Comparative trials of these treatments are warranted to better estimate cost …February 16. The FDA recently approved the first gene therapy for bladder cancer, Ferring Pharmaceuticals’ Adstiladrin (nadofaragene firadenovec-vncg). Almost three-quarters of oncologists surveyed by Zitter Insights expressed at least moderate interest in the agent, and payers said they likely will manage the drug to label.About ADSTILADRIN. Adstiladrin ® (nadofaragene firadenovec-vncg) is a gene therapy developed as a treatment for adult patients with BCG-unresponsive NMIBC. It is a non-replicating adenovirus vector-based gene therapy containing the gene interferon alfa-2b, administered by catheter into the bladder once every three months.Nadofaragene firadenovec-vncg has been studied in a clinical trial program that includes 157 patients with high-grade, BCG-unresponsive NMIBC who had been treated with adequate BCG previously and ...Adstiladrin® (nadofaragene firadenovec-vncg) (Intravesical) Document Number: IC-0691 Last Review Date: 05/04/2023 Date of Origin: 02/02/2023 Dates Reviewed: 02/2023, 05/2023 I. Length of Authorization Coverage will be provided initially for 3 months and may be renewed every 6 months thereafter. II. Dosing LimitsNadofaragene firadenovec (Adstiladrin®) is an intravesical human IFN-α2b gene-mediated therapy that delivers the IFN-α2b gene to increase IFN-α2b expression [94]. In a phase 3 study, a CR of 53.4% at 3 months was reported in patients with CIS, with 24.3% remaining free of high-grade recurrence at 1 year [94].ADSTILADRIN (nadofaragene firadenovec-vncg) is a non-replicating adenoviral vector-based gene therapy for intravesical instillation. It is a recombinant adenovirus serotype 5 vector containing a transgene encoding the human interferon alfa-2b (IFNα2b). ADSTILADRIN has a nominal concentration of 3 x 10 11 vp/mL. Feb 2, 2023 · Adstiladrin® (nadofaragene firadenovec-vncg) (Intravesical) Document Number: IC-0691 Last Review Date: 02/02/2023 Date of Origin: 02/02/2023 Dates Reviewed: 02/2023 I. Length of Authorization Coverage will be provided initially for 3 months and may be renewed every 6 months. II. Dosing Limits A. Quantity Limit (max daily dose) [NDC Unit]: .